GLI1 and cancer: It has been suggested that due to the complexity of signalling inputs into GLI (Ruiz et al, 2007; Stecca and Ruiz, 2010), targeting GLI in cancers may provide a more comprehensive strategy for treating both canonical and non-canonical Hh-pathway-dependent cancers.